Lépjen offline állapotba az Player FM alkalmazással!
Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni
Manage episode 427562766 series 3369804
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:
1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL
https://library.ehaweb.org/eha/2024/eha2024-congress/4136516
2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):
https://library.ehaweb.org/eha/2024/eha2024-congress/422343
3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740
4. ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515
5. HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext
6. Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268
7. Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267
52 epizódok
Manage episode 427562766 series 3369804
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:
1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL
https://library.ehaweb.org/eha/2024/eha2024-congress/4136516
2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):
https://library.ehaweb.org/eha/2024/eha2024-congress/422343
3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740
4. ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515
5. HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext
6. Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268
7. Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267
52 epizódok
सभी एपिसोड
×Üdvözlünk a Player FM-nél!
A Player FM lejátszó az internetet böngészi a kiváló minőségű podcastok után, hogy ön élvezhesse azokat. Ez a legjobb podcast-alkalmazás, Androidon, iPhone-on és a weben is működik. Jelentkezzen be az feliratkozások szinkronizálásához az eszközök között.